JP2013536845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536845A5 JP2013536845A5 JP2013527146A JP2013527146A JP2013536845A5 JP 2013536845 A5 JP2013536845 A5 JP 2013536845A5 JP 2013527146 A JP2013527146 A JP 2013527146A JP 2013527146 A JP2013527146 A JP 2013527146A JP 2013536845 A5 JP2013536845 A5 JP 2013536845A5
- Authority
- JP
- Japan
- Prior art keywords
- dry powder
- inhalation
- magnesium
- inhalation according
- dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 13
- 159000000003 magnesium salts Chemical class 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 239000002245 particle Substances 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 4
- 108010067396 dornase alfa Proteins 0.000 claims 3
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims 3
- 239000000626 magnesium lactate Substances 0.000 claims 3
- 229960004658 magnesium lactate Drugs 0.000 claims 3
- 235000015229 magnesium lactate Nutrition 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 2
- 235000017274 Diospyros sandwicensis Nutrition 0.000 claims 2
- 241000282838 Lama Species 0.000 claims 2
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229940125389 long-acting beta agonist Drugs 0.000 claims 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 2
- 229960002337 magnesium chloride Drugs 0.000 claims 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 2
- 229960003390 magnesium sulfate Drugs 0.000 claims 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims 2
- 239000003195 sodium channel blocking agent Substances 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- -1 Magnesium cations Chemical class 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 1
- 229960002576 amiloride Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 229960001708 magnesium carbonate Drugs 0.000 claims 1
- 235000014380 magnesium carbonate Nutrition 0.000 claims 1
- 235000011147 magnesium chloride Nutrition 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims 1
- 239000004137 magnesium phosphate Substances 0.000 claims 1
- 229960002261 magnesium phosphate Drugs 0.000 claims 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims 1
- 235000010994 magnesium phosphates Nutrition 0.000 claims 1
- 229940091250 magnesium supplement Drugs 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37814610P | 2010-08-30 | 2010-08-30 | |
| US61/378,146 | 2010-08-30 | ||
| US38792510P | 2010-09-29 | 2010-09-29 | |
| US61/387,925 | 2010-09-29 | ||
| US201161431242P | 2011-01-10 | 2011-01-10 | |
| US61/431,242 | 2011-01-10 | ||
| PCT/US2011/049435 WO2012030664A1 (en) | 2010-08-30 | 2011-08-26 | Dry powder formulations and methods for treating pulmonary diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536845A JP2013536845A (ja) | 2013-09-26 |
| JP2013536845A5 true JP2013536845A5 (https=) | 2014-10-09 |
| JP5877201B2 JP5877201B2 (ja) | 2016-03-02 |
Family
ID=45773220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527146A Active JP5877201B2 (ja) | 2010-08-30 | 2011-08-26 | 肺疾患を治療するための乾燥粉末製剤および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9061352B2 (https=) |
| EP (1) | EP2611438B1 (https=) |
| JP (1) | JP5877201B2 (https=) |
| CN (2) | CN105640925B (https=) |
| AU (1) | AU2011296343B2 (https=) |
| CA (1) | CA2809666C (https=) |
| WO (1) | WO2012030664A1 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| CN101801521B (zh) | 2007-05-14 | 2015-06-17 | 纽约州立大学研究基金会 | 生物膜中细菌细胞内的生理学分散响应诱导 |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| EP3470057B1 (en) | 2010-09-29 | 2021-11-03 | Pulmatrix Operating Company, Inc. | Cationic dry powders comprising magnesium salt |
| RU2017144619A (ru) | 2010-09-29 | 2019-02-20 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
| WO2013052844A1 (en) | 2011-10-07 | 2013-04-11 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| CN107596518B (zh) * | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| JP6174684B2 (ja) * | 2012-05-07 | 2017-08-02 | リン，ジン−フェイ，チャン | カルシウム系抗菌材料 |
| EA201590030A1 (ru) * | 2012-07-05 | 2015-09-30 | Арвен Айлак Санайи Ве Тиджарет А.С. | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент |
| WO2014007772A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising glucose anhydrous |
| WO2014007771A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising muscarinic receptor antagonist |
| WO2014021718A1 (en) * | 2012-08-01 | 2014-02-06 | Purac Biochem B.V. | Lactate powder and method for the preparation thereof |
| BR112015010601B1 (pt) * | 2012-11-09 | 2022-07-19 | Civitas Therapeutics, Inc. | Composição farmacêutica e uso da composição |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| EP2754356A1 (en) | 2013-01-15 | 2014-07-16 | Purac Biochem N.V. | Improved nisin production process |
| EP2769630B1 (en) | 2013-02-26 | 2016-04-27 | Purac Biochem N.V. | Improved nisin production process |
| JP6473738B2 (ja) | 2013-04-01 | 2019-02-20 | パルマトリックス，インコーポレイテッド | チオトロピウム乾燥粉末 |
| HK1218720A1 (zh) | 2013-04-30 | 2017-03-10 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
| MX375448B (es) * | 2013-07-18 | 2025-03-06 | Mannkind Corp | Composiciones farmacéuticas en polvo seco estables al calor y métodos. |
| DK2897588T3 (da) * | 2013-11-22 | 2019-08-12 | Teva Branded Pharmaceutical Products R&D Inc | Inhalerbart lægemiddel |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| WO2016057641A1 (en) * | 2014-10-08 | 2016-04-14 | Pulmatrix Operating Company, Inc. | Formulations containing tiotropium, amino acid and acid and methods thereof |
| US20170304198A1 (en) * | 2014-10-08 | 2017-10-26 | Pulmatrix Operating Company, Inc. | Improved stability of dry powders containing tiotropium and amino acid |
| WO2016067252A1 (en) | 2014-10-31 | 2016-05-06 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
| US12121538B2 (en) | 2015-06-04 | 2024-10-22 | Amorphical Ltd. | Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration |
| US10758565B2 (en) | 2015-06-04 | 2020-09-01 | Amorphical Ltd. | Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration |
| US10046007B2 (en) | 2015-06-24 | 2018-08-14 | Prescient Pharma, Llc | Compositions and methods for treatment of short telomere disorders |
| DE102016122768A1 (de) * | 2015-12-02 | 2017-06-14 | Miz Company Limited | Vorrichtung und Verfahren zum Erzeugen einer wasserstoffhaltigen Flüssigkeit |
| EP3525759A1 (en) | 2016-10-14 | 2019-08-21 | Pulmatrix Operating Company, Inc. | Antifungal dry powders |
| AU2017349921B2 (en) | 2016-10-25 | 2023-06-15 | Amorphical Ltd | Amorphous calcium carbonate for treating a leukemia |
| EP3618824A4 (en) * | 2017-05-02 | 2021-06-23 | Neuronasal, LLC | USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| KR102681843B1 (ko) | 2017-09-22 | 2024-07-05 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| PL3675656T3 (pl) * | 2017-10-05 | 2022-02-28 | Purac Biochem B.V. | Proszek mleczanowy i sposoby jego otrzymywania |
| EP3727418B1 (en) * | 2017-12-21 | 2026-04-08 | Merz Pharmaceuticals, LLC | Surfactant formulations for inhalation |
| WO2019138379A1 (en) * | 2018-01-12 | 2019-07-18 | Metimedi Pharmaceuticals Co., Ltd. | Methods of treating chronic inflammatory diseases |
| AU2019225031B2 (en) * | 2018-02-26 | 2024-04-18 | Shin Nippon Biomedical Laboratories, Ltd. | Powder preparation, cartridge, and device |
| AU2019256453B2 (en) * | 2018-04-18 | 2024-10-17 | Cipla Usa Inc. | Methods of treating fungal infections |
| WO2019210515A1 (en) * | 2018-05-04 | 2019-11-07 | Microbase Technology Corp | Microstructured nozzle |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| ES2953293T3 (es) * | 2018-08-07 | 2023-11-10 | Norton Waterford Ltd | Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación |
| EP3846825A4 (en) | 2018-09-05 | 2022-11-02 | Sensory Cloud, LLC | FORMULATIONS AND COMPOSITIONS FOR ORTHO- AND/OR RETRO-NASAL DELIVERY AND RELATED SYSTEMS, METHODS AND ARTICLES |
| US20210361581A1 (en) * | 2018-10-22 | 2021-11-25 | Ioi Oleo Gmbh | Additive for a powder material intended for compaction into shaped bodies |
| EP3886902A1 (en) | 2018-11-30 | 2021-10-06 | CSL Behring AG | Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin |
| RU2714679C1 (ru) * | 2019-03-21 | 2020-02-19 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ моделирования сочетанной патологии метаболического синдрома и хронической обструктивной болезни легких |
| CN109827875A (zh) * | 2019-04-10 | 2019-05-31 | 上海市食品药品检验所 | 一种用于测定吸入制剂溶出度的装置和方法 |
| KR20220038056A (ko) | 2019-07-23 | 2022-03-25 | 아모피컬 리미티드 | 운동 수행능력을 개선시키기 위한 비정질 탄산칼슘 |
| WO2021203001A1 (en) * | 2020-04-03 | 2021-10-07 | Millennium Pharmaceuticals, Inc. | Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme |
| RS63725B1 (sr) * | 2020-05-18 | 2022-12-30 | Orexo Ab | Nova farmaceutska kompozicija za davanje leka |
| CN112163350B (zh) * | 2020-11-02 | 2023-05-23 | 国能黄金埠发电有限公司 | 一种制粉系统双模型的煤粉细度实时在线软测量系统及方法 |
| WO2022187222A1 (en) * | 2021-03-03 | 2022-09-09 | Pulmatrix Operating Company, Inc. | Dihydroergotamine dry power formulations and methods of use |
| WO2023086013A2 (en) * | 2021-11-09 | 2023-05-19 | Agency For Science, Technology And Research | A salt-based antifungal powder platform formulation for aerosolization |
| AR127780A1 (es) | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| AU2022415443A1 (en) * | 2021-12-16 | 2024-07-18 | Alveolus Bio, Inc. | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease |
| WO2025265075A1 (en) * | 2024-06-21 | 2025-12-26 | Parion Sciences, Inc. | Methods of clearing mucus from the lungs |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| US4233405A (en) | 1979-10-10 | 1980-11-11 | Rohm And Haas Company | Process for spray drying enzymes |
| DE3229179C2 (de) | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
| US4637815A (en) | 1985-08-06 | 1987-01-20 | Lemole Gerald M | Irrigational hemostatic solution |
| US5511726A (en) | 1988-09-23 | 1996-04-30 | Battelle Memorial Institute | Nebulizer device |
| US4899914A (en) | 1988-11-04 | 1990-02-13 | Ciba-Geigy Corporation | Method for producing a sterile preservative-free aerosol saline solution |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| US5175152A (en) | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
| US5211944A (en) | 1990-10-12 | 1993-05-18 | Shaman Pharmaceuticals, Inc. | Proanthocyanidin polymers having antiviral activity and methods of obtaining same |
| US5571535A (en) | 1990-11-30 | 1996-11-05 | Flowers; Marianne | Treatment of topical infections |
| JPH0512398A (ja) | 1990-12-28 | 1993-01-22 | Mutoh Ind Ltd | 画像編集方法および装置 |
| US5993805A (en) | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| JPH05123398A (ja) | 1991-11-06 | 1993-05-21 | Tsunemasa Kamiyama | 咽喉保護吸入剤並びに吸入器具 |
| GB2265845B (en) | 1991-11-12 | 1996-05-01 | Medix Ltd | A nebuliser and nebuliser control system |
| US5466680A (en) | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| JP3961029B2 (ja) | 1992-06-24 | 2007-08-15 | 博 木戸 | インフルエンザウィルス感染防止剤 |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5898037A (en) | 1992-11-13 | 1999-04-27 | Marx; Alvin J. | Formulations of magnesium compounds for local application and methods of treatment using the same |
| US5724957A (en) | 1993-01-29 | 1998-03-10 | Aradigm Corporation | Intrapulmonary delivery of narcotics |
| US6098620A (en) | 1993-01-29 | 2000-08-08 | Aradigm Corporation | Device for aerosolizing narcotics |
| US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
| NZ328476A (en) | 1993-06-24 | 1999-05-28 | Astra Ab | Use of a two component insulin preparation in an inhalation device |
| AUPM411494A0 (en) | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
| US5633003A (en) | 1994-03-31 | 1997-05-27 | Cantor; Jerome O. | Use of intratracheally administered hyaluronic acid to ameliorate emphysema |
| JP3414539B2 (ja) | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| JP3061862B2 (ja) | 1994-10-14 | 2000-07-10 | 山之内製薬株式会社 | アゾール誘導体 |
| US5863563A (en) | 1994-10-20 | 1999-01-26 | Alphagene Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
| US5747002A (en) | 1995-04-05 | 1998-05-05 | Genentech, Inc. | Preparation of sodium chloride aerosol formulations |
| US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| US6258341B1 (en) * | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| ES2237767T3 (es) | 1995-04-14 | 2005-08-01 | Nektar Therapeutics | Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada. |
| MX9707862A (es) | 1995-04-14 | 1997-11-29 | Glaxo Wellcome Inc | Inhalador de dosis medida para el propionato de fluticasona. |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| US20050054682A1 (en) | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
| GB9606677D0 (en) | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| DE19653969A1 (de) | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| CN1169520C (zh) | 1997-09-29 | 2004-10-06 | 耐科塔医药公司 | 多孔微粒及其使用方法 |
| GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| AU749751B2 (en) | 1998-04-08 | 2002-07-04 | Eli Lilly And Company | Pulmonary and nasal delivery of raloxifene |
| US5883084A (en) | 1998-06-08 | 1999-03-16 | Clarion Pharmaceuticals Inc. | Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| FR2780285B1 (fr) | 1998-06-29 | 2001-10-05 | Goemar Lab Sa | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions |
| WO2000000215A1 (en) | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| US6333051B1 (en) | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
| US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| AU4979700A (en) | 1999-05-03 | 2000-11-17 | Battelle Memorial Institute | Compositions for aerosolization and inhalation |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
| US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
| AU768299B2 (en) * | 1999-08-25 | 2003-12-04 | Alkermes, Inc. | Formulation for spray-drying large porous particles |
| DE60025019T2 (de) | 1999-10-29 | 2006-08-24 | Nektar Therapeutics, San Carlos | Trockenpulverzusammensetzungen mit verbesserter dispersivität |
| AU772096B2 (en) | 2000-03-14 | 2004-04-08 | Sumika Enviro-Science Co., Ltd. | Method for denaturing allergens |
| ES2525087T5 (es) | 2000-05-10 | 2018-06-28 | Novartis Ag | Polvos basados en fosfolípidos para administración de fármacos |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| PT1296651E (pt) | 2000-06-27 | 2008-02-12 | Vectura Ltd | Método para fazer partículas para serem usadas numa composição farmacêutica |
| US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
| AU2001278131A1 (en) | 2000-08-01 | 2002-02-13 | Shofner Engineering Associates, Inc. | Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient |
| US6572849B2 (en) | 2000-09-20 | 2003-06-03 | Lee Shahinian, Jr. | Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications |
| EP2283818B1 (en) * | 2000-11-30 | 2017-08-02 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| CA2432319A1 (en) | 2000-12-21 | 2002-07-18 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
| PT2301524E (pt) | 2000-12-27 | 2013-07-10 | Gilead Sciences Inc | Aztreonam inalável sem arginina para tratamento e prevenção de infecções bacterianas pulmonares |
| US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030138403A1 (en) | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
| WO2003035028A1 (en) | 2001-10-19 | 2003-05-01 | Nektar Therapeutics | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
| CA2465675C (en) | 2001-11-20 | 2008-06-10 | Advanced Inhalation Research, Inc. | Improved particulate compositions for pulmonary delivery |
| IL161446A0 (en) | 2001-11-26 | 2004-09-27 | Daiichi Suntory Pharma Co Ltd | Medicinal compositions for nasal absorption |
| WO2003072080A1 (en) | 2002-02-22 | 2003-09-04 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
| JP4384503B2 (ja) | 2002-03-20 | 2009-12-16 | アルカーメス，インコーポレイテッド | レボドパの肺送達 |
| US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
| GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| US20050220720A1 (en) | 2002-05-02 | 2005-10-06 | David Edwards | Formulations limiting spread of pulmonary infections |
| EP1503744A1 (en) | 2002-05-13 | 2005-02-09 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
| JP4533134B2 (ja) | 2002-06-10 | 2010-09-01 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ |
| WO2004002551A2 (en) | 2002-06-28 | 2004-01-08 | Advanced Inhalation Research, Inc. | Inhalable epinephrine |
| US7112572B2 (en) | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
| WO2004030659A1 (en) | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| WO2004047735A2 (en) | 2002-11-22 | 2004-06-10 | Mang Yu | Broad spectrum anti-viral therapeutics and prophylaxis |
| US7534781B2 (en) | 2003-03-21 | 2009-05-19 | Dsm Ip Assets B.V. | Crystalline amoxicillin trihydrate powder |
| CN1194062C (zh) | 2003-04-04 | 2005-03-23 | 王泽斌 | 一种融雪融冰组合物及其制备方法和应用 |
| EA010948B1 (ru) | 2003-05-01 | 2008-12-30 | Инноджен Калбиотех Пте Лтд. | Фармацевтическая композиция, содержащая лактат, и ее применение |
| JP2009514779A (ja) | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
| GB0324918D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
| GB0324897D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
| KR20050056622A (ko) | 2003-12-10 | 2005-06-16 | 주식회사 대우일렉트로닉스 | 플레쉬롬 다운로드 장치 |
| EP1701714A2 (en) | 2004-01-07 | 2006-09-20 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
| US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| SE528121C2 (sv) | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
| CA2602596A1 (en) | 2004-03-30 | 2005-10-13 | Malcolm King | Compositions and methods for improved mucus function |
| US20050281740A1 (en) | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
| MX2007000979A (es) | 2004-07-26 | 2007-07-11 | Cotherix Inc | Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada. |
| US20060073173A1 (en) | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| US8627821B2 (en) | 2005-01-10 | 2014-01-14 | Pulmatrix, Inc. | Method and device for decreasing contamination |
| WO2006102438A2 (en) | 2005-03-23 | 2006-09-28 | Ihc Intellectual Asset Management, Llc | Methods and compositions for irrigation of mucosal tissues |
| EP1888257A1 (en) | 2005-05-05 | 2008-02-20 | Pulmatrix, Inc. | Ultrasonic aerosol generator |
| EP2402001A1 (en) | 2005-05-18 | 2012-01-04 | Pulmatrix, Inc. | Formulations for alteration of biophysical properties of mucosal lining |
| US7838532B2 (en) | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| GB0520794D0 (en) | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
| GB0523576D0 (en) | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
| US20070202051A1 (en) | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
| WO2008025560A1 (en) | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
| US20080063722A1 (en) | 2006-09-08 | 2008-03-13 | Advanced Inhalation Research, Inc. | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) |
| US8501255B2 (en) | 2006-12-14 | 2013-08-06 | Purac Biochem B.V. | Particulate composition comprising calcium lactate and calcium citrate microparticles |
| GB0625322D0 (en) | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
| ES2423991T3 (es) | 2008-02-04 | 2013-09-26 | Pfizer Limited | Forma polimórfica de un derivado de [1,2,4]triazolo[4,3-a]piridina para el tratamiento de enfermedades inflamatorias |
| NO2252275T3 (https=) | 2008-02-13 | 2018-04-28 | ||
| EP2098219A1 (en) * | 2008-03-05 | 2009-09-09 | PARI Pharma GmbH | Macrolide compositions having improved taste and stability |
| WO2009140587A1 (en) | 2008-05-15 | 2009-11-19 | Novartis Ag | Pulmonary delivery of a fluoroquinolone |
| EP2379070A4 (en) | 2008-07-21 | 2013-11-13 | Imi Internat Medical Innovations D B A Procris Pharmaceuticals | WATER BASED TOPICAL STABLE PHARMACEUTICAL CREAMES AND METHODS FOR PREPARING AND USING SAME |
| GB0818476D0 (en) | 2008-10-09 | 2008-11-12 | Vectura Delivery Device Ltd | Inhaler |
| JP2012522011A (ja) | 2009-03-26 | 2012-09-20 | パルマトリックス，インコーポレイテッド | 気道感染症を治療するための医薬製剤および方法 |
| CA2754684A1 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
| CA2754670A1 (en) | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Anti-influenza formulations and methods |
| US20120058198A1 (en) | 2009-03-26 | 2012-03-08 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
| CA2754691C (en) | 2009-03-26 | 2019-07-30 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| PT106094A (pt) | 2012-01-13 | 2013-07-15 | Hovione Farmaciencia S A | Administração por inalação de formulações com dose elevada |
-
2011
- 2011-08-26 AU AU2011296343A patent/AU2011296343B2/en active Active
- 2011-08-26 CN CN201610054941.2A patent/CN105640925B/zh active Active
- 2011-08-26 JP JP2013527146A patent/JP5877201B2/ja active Active
- 2011-08-26 WO PCT/US2011/049435 patent/WO2012030664A1/en not_active Ceased
- 2011-08-26 CA CA2809666A patent/CA2809666C/en active Active
- 2011-08-26 EP EP11751775.5A patent/EP2611438B1/en active Active
- 2011-08-26 CN CN201180052479.8A patent/CN103200938B/zh not_active Expired - Fee Related
- 2011-08-26 US US13/817,963 patent/US9061352B2/en active Active
-
2015
- 2015-05-20 US US14/717,243 patent/US9233158B2/en active Active
-
2017
- 2017-09-29 US US15/720,445 patent/US20180153996A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536845A5 (https=) | ||
| AU2010229724B2 (en) | Pharmaceutical formulations and methods for treating respiratory tract infections | |
| JP2013540123A5 (https=) | ||
| CA2754677A1 (en) | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis | |
| US20120083531A1 (en) | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining | |
| RU2017144619A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
| ES3033142T3 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| JP2011520911A5 (https=) | ||
| JP2013224331A5 (https=) | ||
| JP2012503668A5 (https=) | ||
| CN106488770A (zh) | 用于治疗copd的福莫特罗和布地奈德的组合 | |
| RU2015129076A (ru) | Арилалкил- и арилоксиалкил-замещенные соединения, блокирующие эпителиальный натриевый канал | |
| JP2017530988A5 (https=) | ||
| WO2017101696A1 (zh) | 治疗急慢性呼吸困难的西药组合物及其制备方法 | |
| JP2013522295A5 (https=) | ||
| CA2701388A1 (en) | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions | |
| JP2023528883A (ja) | 呼吸器系傷害改善用医薬組成物及び呼吸器系傷害改善用医薬組成物の製造のための用途 | |
| HK1156847B (en) | Pharmaceutical formulations and methods for treating respiratory tract infections | |
| NZ767296B2 (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| NZ767296A (en) | Liquid inhalation formulation comprising rpl554 |